Meeting
2013 ASCO Annual Meeting
BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+ HER2- advanced breast cancer.
Authors
Bent Ejlertsen
Danish Breast Cancer Cooperative Group Statistical Center Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark
Bent Ejlertsen , Guy Heinrich Maria Jerusalem , Sara A. Hurvitz , Richard H. De Boer , Tanya Taran , Tarek Sahmoud , Howard A. Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01783444
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS660)
DOI
10.1200/jco.2013.31.15_suppl.tps660
Abstract #
TPS660
Poster Bd #
16C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+ HER2- metastatic breast cancer.
First Author: William John Gradishar
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
Poster
2013 ASCO Annual Meeting
UNIRAD: Multicenter, double-blind, phase III study of everolimus plus ongoing adjuvant therapy in ER+ HER2- breast cancer.
First Author: Thomas Denis Bachelot
Poster
2012 Breast Cancer Symposium
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
First Author: Francis Arena